Top news from MedWatch this week
Monday
Health ministers back EU Commission’s staggered approach to new medtech requirements
Novo Nordisk to launch sought-after obesity drug in Denmark
No reimbursement makes Wegovy an option for few Danes, says professor
Top news from MedWatch this week
Tuesday
Novo Nordisk to test app and heart disease antibody in phase III trial
Obesity drug Wegovy’s European rollout delayed after US setbacks
The world’s biggest sovereign wealth fund keeps buying and selling GN stock – but won’t say why
Eli Lilly expects 2023 revenue to pass USD 30bn mark
Pfizer predicts billion-dollar RSV sales
GN Group’s science-based climate goals gain approval
Wednesday
Christmas strike puts British nurses on medtech companies’ naughty lists
UK watchdog to probe antibiotic prices amid strep A outbreak
New Danish government to extend a hand to life science companies
Thursday
Ambu chair rejects shareholders association’s suggested ownership change
New funding fuels Minervax’s hope to win strep B vaccine race despite huge competition
Genmab CEO profits USD 5m from share sale
Friday
CHMP rounds off 2022 with five recommendations
Novo Nordisk acknowledges UK marketing violation
